评论
打印
Dr. Anthony Fauci doesn't get too excited about the results of animal studies, and he doesn't make house calls.
对于动物研究的结果，安东尼·弗契博士并不是那么激动，他也从不上门亲访。
But when a drug already taken by thousands of people for intestinal conditions appeared to control the monkey version of HIV, it got the attention of the director of the National Institutes of Allergy and Infectious Diseases.
但是，当一种被成千上万人用于肠道环境的药似乎能够控制猴类艾滋时，这引起了这名国家过敏和传染病研究所主任的注意。
Fauci hopped on a plane to Cambridge, Mass., to personally tell Japan's Takeda Pharmaceutical Co's U.S. representatives that their drug may offer a dramatic advance in the fight against AIDS.
弗契乘坐飞往马萨诸塞州剑桥的飞机，亲自告诉日本武田药业公司的美国代表，他们的药物可能在抗击艾滋病方面取得了显著进步。
Takeda's drug suppressed the virus to undetectable levels in eight monkeys, some for two years.
武田公司的药物将八个猴子体内的细菌抑制到了不可检测到的程度，有的甚至长达两年。
The findings raise hopes for a so-called "functional cure" – a treatment that puts the disease in sustained remission.
这一发现燃起了所谓“功能性治愈”的希望--这种治疗方法可以让疾病得到持续缓解。
"The data was so dramatic," said Fauci, who has made AIDS research his life's work.
将艾滋病研究当作终身事业的弗契说道：“这一数据很激动人心。”
The drug is one of several promising ideas heading into early-stage human trials, all seeking to help patients control the virus that causes AIDS for extended periods without daily antiretroviral therapy (ART).
该药品是进入早期人体实验的几款很有希望的药物之一，所有这些药物都试图在不需要每天进行抗逆转录病毒治疗（ART）的情况下，帮助患者长期控制艾滋致病病毒。
